CIK 0001714899 · Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 463872213
- Phone
- (650) 866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 8-K Event Regulation FD disclosure
- 4 Planned sale Director sold 30,000 shares at $20.25 ($607,500)
- 4 Planned sale Director sold 3,080 shares at $20.91 ($64,403)
- 144 Insider Sale of Securities
- 4 Option exercise COFO and Secretary acquired 6,708 shares (option exercise)
- 144 Insider Sale of Securities
- 4 Option exercise Chief Medical Officer acquired 17,845 shares (option exercise)
- 4 Option exercise COFO and Secretary acquired 20,516 shares (option exercise)
- 8-K Event Bylaws or fiscal year change
- 4 Planned sale Director sold 59,441 shares at an average $32.51 ($1,932,665)
- 4 Planned sale COFO and Secretary sold 15,558 shares at an average $29.91 ($465,286)
- 4 Planned sale Director sold 1,020 shares at $30.00 ($30,600)
- SC 13G Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 144 Insider Sale of Securities
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 144 Insider Sale of Securities
- 10-Q Report Quarterly Report
Page 7 of 40 · 789 filings